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Abstract Phosphotyrosine binding (PTB) domains are structur-
ally conserved modules found in proteins involved in numerous
biological processes including signaling through cell-surface
receptors and protein trafficking. While their original discovery
is attributed to the recognition of phosphotyrosine in the context
of NPXpY sequences ^ a function distinct from that of the
classical src homology 2 (SH2) domain ^ recent studies show
that these protein modules have much broader ligand binding
specificities. These studies highlight the functional diversity of
the PTB domain family as generalized protein interaction
domains, and reinforce the concept that evolutionary changes
of structural elements around the ligand binding site on a
conserved structural core may endow these protein modules
with the structural plasticity necessary for functional versatil-
ity. ß 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
Key words: Phosphotyrosine binding domain;
Three-dimensional structure; Fibroblast growth factor
receptor substrate 2; Insulin receptor substrate-1; Numb;
Shc; Suc1-associated neurotrophic factor target; X11
1. Introduction
The phosphotyrosine binding (PTB) domain, also known as
the phosphotyrosine interaction domain, is a modular inter-
face of V100^170 amino acids important for protein^protein
interaction [1^4]. First independently identi¢ed in the signal-
ing proteins Shc [5^7] and insulin receptor substrate 1 (IRS-1)
[8], this domain was discovered as an alternative to the src
homology 2 (SH2) domain for phosphotyrosine recognition.
Speci¢cally, the PTB domains of Shc and IRS-1 preferentially
bind to phosphorylated proteins containing an NPXpY motif
(where pY is phosphotyrosine and X is any amino acid), with
hydrophobic amino acids N-terminal to this sequence confer-
ring additional speci¢city [8^13]. Recent studies show that
PTB domain-like protein modules can also bind to proteins
independent of tyrosine phosphorylation or even the canon-
ical NPXY motif. For example, the PTB domains of the neu-
ron-speci¢c X11 protein and Fe65 both bind to a peptide
derived from a region of L-amyloid precursor protein
(L-APP) containing a non-phosphorylated NPTY sequence
[14,15]. The Drosophila Numb PTB domain recognizes non-
NPXY sequences, including GFSNMSFEDFP in a Ser/Thr
protein kinase, Nak [16,17], and a GPY motif, identi¢ed
through screening of a tyrosine-oriented synthetic peptide li-
brary [18,19]. In addition, the PTB domains of Shc [20] and
mammalian protein Disabled (Dab) [21] can also interact with
phospholipids. The enormous functional versatility of the
PTB domain family is further highlighted by the PTB domain
of membrane-anchored adapter proteins [22^24], SNT-1/2
(suc1-associated neurotrophic factor target; also known as
¢broblast growth factor receptor substrate 2K/L) that has
been shown to be capable of interacting with unrelated se-
quences from two di¡erent receptors, i.e. a tyrosine-phosphor-
ylated NPXpY motif in tyrosine receptor kinases (TRKs)
[25,26] and a non-phosphorylated segment in ¢broblast
growth factor receptor (FGFRs) that contains no tyrosine
or asparagine residues [27,28].
Unlike SH2 domains, PTB domains share low sequence
homology amongst themselves and exhibit extremely high li-
gand binding selectivity ^ the IRS-1 PTB domain does not
bind to the NPXpY peptides derived from known Shc binding
sites in the TRKs and epidermal growth factor receptors
[12,29]. Despite their di¡erences in amino acid sequence and
ligand binding speci¢cities, these PTB domains adopt a re-
markably similar sca¡old that is identical to that of the pleck-
strin homology (PH) domain, which is known to bind to
acidic phospholipids and localize proteins to the plasma mem-
brane [30^32]. Recent structural studies on PTB domains re-
veal how a conserved protein modular domain has evolved to
acquire the structural plasticity necessary to recognize a di-
verse set of biological ligands. In this minireview, we examine
the unique structural features of PTB domains and their
modes of ligand recognition.
2. A PTB/PH domain superfold
The three-dimensional structures of ¢ve PTB domains de-
termined so far, in the proteins Shc [33], IRS-1 [34^36], X11
[37], Numb [17,19], and SNT-1 [38], show that all PTB do-
mains adopt the structurally conserved PH domain-like fold
[30,31], as highlighted in blue in the Shc PTB domain (Fig. 1).
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This PH domain fold consists of a L-sandwich containing two
nearly orthogonal, antiparallel L-sheets capped at one end by
a C-terminal K-helix (K3 in Shc). Despite the divergent se-
quences of the peptide ligands (see below), the major ligand
binding site is located similarly in these di¡erent PTB do-
mains, as illustrated by an elongated cleft formed by L5 and
K3 in Shc. Although this highly conserved superfold is also
seen in other functionally distinct protein interaction modules
[39], which include the PH domain that commonly binds to
phospholipids [31,32,40^43], the EVH1 domain (enabled/
VASP homology 1) that binds proline-rich sequences [44,45],
the Ran binding domain that interacts with Ran-GTPase [46],
and lobe F3 of the FERM domain (band four-point-one,
ezrin, radixin, moesin homology) that functions in protein
localization to the plasma membrane [47,48], the location of
this ligand binding site between L5 and the C-terminal K helix
(K3) is unique to the PTB domain family. Di¡erences in li-
gand speci¢city among PTB domains are due to variations of
structural features that lie outside the conserved secondary
structure elements that comprise the basic sca¡old.
3. NPXpY recognition
The structures of the Shc and IRS-1 PTB domains in com-
plex with high-a⁄nity peptides reveal the structural basis of
NPXpY motif recognition. The structure of the Shc PTB do-
main in complex with a phosphopeptide derived from the
nerve growth factor receptor TRKA (HIIENPQpYFSDA)
was solved by nuclear magnetic resonance (NMR) [33], where-
as the IRS-1 PTB domain structures were determined by
NMR [34] and X-ray crystallography [35] when bound to an
interleukin-4 receptor (IL-4R) peptide (LVIAGNPApYRS) or
to a modi¢ed insulin receptor (IR) peptide (LYASSNPApY,
where E(pY31) in the wild type sequence was changed to an
alanine for higher-a⁄nity binding), respectively. Despite the
lack of sequence homology between Shc and IRS-1, the PTB
domains share a common fold, and the conformation and
orientation of the phosphopeptides in the complexes are sim-
ilar. The residues NPQpY in TRKA or NPApY in IR and IL-
4R phosphopeptides form type I L-turns. Unlike SH2 do-
mains [49,50], remarkably, arginine residues that interact di-
rectly with the phosphotyrosine on the protein surface are
conserved only in three-dimensional space but not in the se-
quences of the Shc and IRS-1 PTB domains. The side chain
atoms of N(pY33) form speci¢c intra- and intermolecular
hydrogen bonds to the peptide residue at the (pY31) position
and to protein residues, explaining its crucial structural role in
high-a⁄nity binding to PTB domains [9^11]. The N-termini of
both phosphopeptides adopt an extended conformation and
meld into the second L-sheet of the protein through anti-par-
allel L-sheet interactions with L5.
Two divergent mechanisms are employed by the PTB do-
mains to recognize hydrophobic residues N-terminal to the
NPXpY motif. In Shc, L(pY35) of TRKA peptide binds in
a deep hydrophobic pocket formed between L5 and K3 [33],
whereas in IRS-1, hydrophobic residues at the (pY36) and
(pY38) positions in the IL-4R or IR phosphopeptides form
extensive interactions with hydrophobic sites of the protein
located on the surface of the second L-sheet [34,35]. The anal-
ogous site in Shc is covered by a loop and the N-terminal
portion of an K-helix (K2), making it unavailable for ligand
binding.
Additional di¡erences in ligand selectivity between these
two PTB domains are further attributed to the di¡erences in
ligand recognition. For example, the IRS-1 PTB domain fa-
vors a small hydrophobic amino acid such as alanine at the
(pY31) position for high-a⁄nity binding ^ when A(pY31) in
IL-4R is substituted by a glutamate, a 30-fold loss in binding
to IRS-1 is observed [12,29,35]. This result can be explained
by the PTB domain structure, in which A(pY31) interacts
with a hydrophobic patch composed of three methionines,
i.e. M209, M257 and M260 [34,35]. An alanine to glutamate
mutation would result in an unfavorable interaction with the
three methionines. It is interesting to note that IL-4R contains
the optimal NPApY sequence (at pY497) for high-a⁄nity li-
gand binding to the IRS-1 PTB domain, whereas the known
IRS-1 binding site in IR at pY960 contains a non-optimal
NPEpY motif. Indeed, it has been shown that while highly
speci¢c, the IRS-1 PTB domain binding to the phosphorylated
NPEpY motif in IR (KDW85 WM) is signi¢cantly weaker than
that to the NPApY sequence in IL-4R (KD = 1.8 WM) [29].
These striking results emphasize the notion that biological
interactions of high speci¢city but relatively low a⁄nity may
be just as important as those with high speci¢city and high
a⁄nity, allowing for additional regulation in signal transduc-
tion.
4. Non-NPXpY binding
Structural studies of the PTB domains from X11, Numb
and SNT-1 have provided further insights into how the con-
served PH domain-like fold can recognize non-phosphorylat-
ed NPXY sequences or even sequences lacking the NPXY
motif. The PTB domain of X11 binds to a non-phosphorylat-
ed peptide (QNGYENPTYKFFEQ) derived from L-APP with
high a⁄nity (KD = 0.32 WM) [14,37]. The crystal structure of
the complex shows that the peptide, bound between L5 and
the C-terminal helix (K2), forms an antiparallel L-strand with
a L-turn (at the NPTY), followed by a 310 helix at the C-ter-
Fig. 1. Three-dimensional structure of the Shc PTB domain in com-
plex with a tyrosine phosphorylated peptide derived from a se-
quence in TRKA containing pY490. The core PTB domain fold is
shown in blue while the additional structural elements are in green.
The phosphopeptide is depicted in red.
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minus (consisting of the KFFE residues) [37]. While Y(Y35)
does interact with the protein residues, most interestingly, the
two aromatic residues F(Y+2) and F(Y+3) in the 310 helix
have extensive contacts with the protein residues in K2, which
is longer by three turns as compared to the structurally anal-
ogous K3 in Shc. These interactions shown in the structure
explain a 10-fold reduction in binding a⁄nity when either of
these phenylalanine residues is mutated to alanine [37]. This
structure shows that the lack of coordination of phosphotyr-
osine by arginine residues, as seen in the Shc and IRS-1 PTB
domains, can be compensated for by hydrophobic interactions
with the surface on the X11 PTB domain for additional in-
teractions to form a stable complex with the non-phosphory-
lated NPTY sequence of L-APP. Thus, tyrosine phosphoryla-
tion, in the case of L-APP, does not enhance its a⁄nity for the
X11 PTB domain [37].
The solution structure of the Drosophila Numb PTB do-
main solved in complex with a peptide (GFSNMSFEDFP)
from the C-terminal tail of a serine/threonine protein kinase,
Nak, has extended our understanding of how this PTB do-
main recognizes a ligand lacking the NPXY consensus se-
quence [16,17]. The structure reveals that the N-terminal res-
idues (GFS) of the Nak peptide adopt an extended
conformation to bind between L5 and the C-terminal K helix
(K3), and the NMSFEDF sequence forms two consecutive
L-turns [17]. While Numb recognition of Nak residues
F(F35) and those in the ¢rst L-turn (NMSF) is similar to
that of the X11 PTB domain recognition of L-APP, binding
of the C-terminal L-turn residues (FEDF) involves protein
residues located in the L4/L5 and L6/L7 loops. This general
mode of interaction may be used to extrapolate our under-
standing of the structural mechanism of the Numb PTB do-
main binding to an NPAY sequence of the protein Lnx, an-
other reported biological target of Numb [51]. The structural
versatility of the Numb PTB domain in its ligand binding cleft
between L5 and C-terminal K helix is further illustrated by its
high-a⁄nity association with a helical turn-forming peptide
(AYIGPpYL), identi¢ed through screening of a synthetic pep-
tide library [18,19]. This unique mode of interaction with the
GPpY sequence remains to be demonstrated as a biologically
relevant function for the Numb PTB domain.
The SNT-1 PTB domain serves to further underscore
the idea that the structural plasticity of the conserved PTB
domain fold results in enhanced functional versatility [22^24].
This single PTB domain is capable of binding not only to the
canonical NPXpY motif in TRKs [23^26], but also to a jux-
tamembrane region in FGFR containing no tyrosine or aspar-
agine residues [27,28]. The recent solution structure of the
SNT-1 PTB domain/human FGFR1 peptide (HSQMAVH-
KLAKSIPLRRQVTVS) complex shows that the peptide
wraps around the protein with an unusual backbone confor-
mation containing two nearly 90‡ turns that are oriented or-
thogonal to each other (Fig. 2) [38]. The C-terminal QVTVS
segment of the peptide adopts an antiparallel L-strand sand-
wiched between L5 and L8, forming an intermolecular L-sheet.
This unique L8, extended from the C-terminal K helix (K1), is
not found in other PTB domains. On the other side of the
L-sandwich, the peptide embeds its N-terminal MAVH seg-
ment into a large hydrophobic cavity bounded by the three
loops connecting L1/L2, L3/L4 and L6/L7. Moreover, the
LAKSIPL sequence located in the center of the peptide binds
to otherwise solvent-exposed hydrophobic residues on the
surface of the second L-sheet. In addition to hydrophobic
interactions, complementary electrostatic interactions are
observed, largely localized at the two turns in the peptide.
This extensive network of intermolecular interactions con-
fers the high speci¢city to the association between SNT-1
and FGFR1. It is not yet clear how SNT-1 interacts with
the tyrosine-phosphorylated NPXpY sequence of TRKs
(8XNPXpY, where 8 is a bulky hydrophobic amino acid).
Because the conserved arginine residues (R63 and R78) that
are essential for the important phosphotyrosine binding activ-
ity are structurally analogous to those in the IRS-1 PTB do-
main, and the requirement for a large hydrophobic residue at
the (pY35) position for high-a⁄nity association, binding of
the NPXpY peptide likely involves regions including L5 and
K1 in SNT-1 [38,52].
5. Unifying features?
The term ‘PTB’ is an inaccurate representation of the activ-
ities of this family of protein modules, but unifying features
do exist. Despite the structural variations and the di¡erences
in ligand speci¢cities, four major contact points appear to be
crucial for PTB domain/ligand association. The location of
these contact points is highlighted using the basic core ele-
ments of the SNT-1 PTB domain/FGFR1 peptide complex
as an example (Fig. 2): (A) a ligand always adopts an anti-
parallel L-strand forming an extension of the second L-sheet
of the protein. The length of the L-strand, bound between L5
and the C-terminal K helix, is in£uenced by its additional
interactions with the protein, such as L8 in SNT-1; (B) a
ligand often contains an NPX(p)Y motif or a related sequence
Fig. 2. Three-dimensional structure of the SNT-1 PTB domain in
complex with a peptide derived from the juxtamembrane region of
human FGFR1. The core PTB domain fold is illustrated in blue,
additional structural elements in green and the peptide in red. Or-
ange dots indicate the location of residues C-terminal to the
L-strand of a putative PTB domain ligand. Highlighted with yellow
stars are the general features of ligand recognition by the PTB do-
main fold: (A) the L-strand conformation of a ligand that melds
into the second L-sheet of the PTB domain through antiparallel
L-sheet interactions with L5; (B) an NPX(p)Y or related sequence
with type I L-turn propensity; (C) the C-terminal speci¢city of a li-
gand achieved by phosphotyrosine-dependent or -independent inter-
actions; and (D) the N-terminal speci¢city of a ligand conferred by
hydrophobic residue(s) up to (pY35) position. Note that the struc-
ture of the SNT-1 PTB domain/hFGFR1 peptide complex is used
here to illustrate the general location of the major contact points
for ligand recognition by PTB domains, and not all these contacts
are necessary for hFGFR1 recognition by the SNT-1 PTB domain.
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with a type I L-turn propensity. This asparagine residue at the
(Y33) position plays a key structural role in L-turn formation
through intra- and intermolecular hydrogen bonds. This turn
may be important for positioning a phosphotyrosine for co-
ordination with solvent-exposed basic residues in the protein,
or for anchoring C-terminal residues of the ligand for forming
stabilizing interactions with the protein; (C) ligand residues
C-terminal to the L-strand (either phosphotyrosine or hydro-
phobic in nature) form additional contacts with the protein;
and (D) ligand residues N-terminal to the L-strand can form
additional interactions with the PTB domain. These interac-
tions could involve regions of the protein including (i) the
hydrophobic core between the L5 and C-terminal K helix,
(ii) the surface residues of the second L-sheet, and (iii) the
hydrophobic pocket located on the other side of the L-sand-
wich opposite to L5. It is important to note that only the
L-strand conformation appears absolutely required in biolog-
ically relevant ligands. The other major contacts can be used
together or in combination to establish speci¢c associations
with the PTB domain. Together, these structural studies illus-
trate how functional diversity of PTB domains can be
achieved by evolutionary changes of the structural features
at the ligand binding sites outside the conserved sca¡old.
Because of low protein sequence homology, secondary and
tertiary structures, which contain more conserved, unifying
features of PTB domains, may be better for identifying new
family members and assigning their functions. It would not be
surprising to see other unexpected modes of ligand recogni-
tion emerging from three-dimensional structures of new PTB
domains in complex with their biological ligands.
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